RHINOMED’S MUTE™ SUCCESSFUL IN DEMONSTRATING EFFICACY AND BENEFIT IN SNORING TRIAL

RHINOMED’S MUTE™ SUCCESSFUL IN DEMONSTRATING EFFICACY AND BENEFIT IN SNORING TRIAL

2 December 2014

Melbourne technology firm, Rhinomed (ASX:RNO) today announced the topline results from its independent trial in snoring, sleep quality and night time nasal congestion which successfully demonstrated significant benefit of its new Mute nasal technology. The Company has submitted applications to the European, US and Australian regulatory authorities that will allow sale of the Mute technology to commence.

The OTC snoring, sleep quality and night time nasal congestion market is a multi-billion dollar global market in which there are limited effective solutions. According to the National Sleep Health Foundation 40% of Australian males and 30% of Australian women snore. This has a significant impact on sleep quality of both the snorer and their partner.